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To keep policy on the right track, we need to under-
stand better how we can support medical innova-
tion while addressing the very important and very
real concerns about the costs of health care that are
facing us today. I think these issues are just going to
get more pressing in the years ahead.
Pharmacoeconomics is an important foundation
for doing this. It addresses not only cost, but also
quality of life, functional status, and the impact of
new and existing drugs on the lives of family and
friends and society as a whole. If we want to truly
understand the value of a new medical treatment or
an existing medical treatment, and the value of
health policies that might inﬂuence its use, we need
to pay a lot of attention to these issues. It is not suf-
ﬁcient to just look at the impact of new proposals
for Medicare coverage, or new reforms in the way
FDA does business, in terms of their impact on cost
alone.
We need to look at quality ﬁrst and foremost,
and that means looking at value in health care. This
is getting to be, as I said, an extremely pressing
problem. The progress that we are seeing today in
medical care is facing some important barriers and
obstacles. I think this is going to be the biomedical
century, and I have talked a lot about that in my
speeches to more general audiences, with all the
breakthroughs that are coming in the labs today in
genomics, proteomics, and really understanding the
molecular foundations of diseases in individual
patients. The potential is there for bringing truly
valuable treatments, truly individualized effective
treatments to patients in the years ahead. But we are
not seeing that yet.
Right now what we are seeing in terms of drug
development is more time and more cost than ever
before. Bringing a new drug to market can often
take a dozen years or more; it requires input from
all kinds of experts, ranging from the basic scientist
to the clinical researchers. The clinical researchers
are a species that I am very concerned about today,
having enough people doing it, and having enough
talent and interaction with increasingly important
areas of basic science and product development.
We see this at the Food and Drug Administration
(FDA), where we need pharmacology experts, clini-
cians, and others involved in the review process to
make it work efﬁciently, so it is even more impor-
tant to have similar expertise in product develop-
ment. But what we are seeing now is more and more
cost. According to a recent study by Tufts Univer-
sity, the cost of bringing a new drug to market now
is almost 900 million dollars, and I know there has
been some dispute out there about whether that
number is an accurate one or not, but I think there
is no disputing the fact that the number has gotten
a lot bigger, about twice as large, according to Tufts,
as it was a decade ago.
I think there is complete consensus among policy
makers that because the process for developing a
drug is getting longer in general, not shorter, the
process for clinical trial implementation for getting
a product to market is getting more expensive and
generally more time consuming. It is getting more
expensive to bring a product to market, and at the
same time we are seeing a decline in the number of
new products that are getting to the agency. This
past year the FDA approved fewer new molecular
entities, the truly new drugs, than in the history of
our prescription drug user fee program in more than
a decade. So despite more research, more new drugs
under investigation (INDs), and more investiga-
tional studies going on than ever, the products that
are actually reaching us are at a lower level than at
any other time in the past.
We, therefore, are looking at some reasons for
that. I think a major reason is that the nature of bio-
medical research is changing a little bit, and a lot of
investment is going into genomics activities and
other activities that have not yet sent products all
the way through the pipeline to us, and to the mar-
ket. But it is a cause for concern, and a cause for
caution that if we continue on this trajectory of ris-
ing cost of product development, if we continue on
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the course of policies that may, in their efforts to
control costs (which is an urgent public policy need)
do not encourage innovation at the same time and
to the same degree, we might not snap out of this
slump, or at least we may not do it as quickly as
would be optimal from the standpoint of improving
public health.
I do not think the future needs to be like that, and
I do not think it will be. I think we can ﬁnd ways to
reduce the cost of developing new and more effec-
tive drugs and medical technologies. And at the
FDA I can tell you that we are committing to doing
all we can to fulﬁll our part in this challenging proc-
ess today. And I think, in particular, you all, through
outcomes research and pharmacoeconomics, have
much to contribute as well.
A lot of people have asked, given my back-
ground, which really is economics and outcomes
research, whether when I talk about more value in
health care that means the FDA is going to start
doing cost-beneﬁt analysis itself of the products that
it regulates. The answer to that is no, that is not part
of our mission. We focus on risk-beneﬁt analysis for
determining whether a product is safe and effective.
And cost-beneﬁt analysis is outside our mandate.
We are thinking about whether there are ways that
we can provide some clearer guidance to the
increasing number of companies that want to talk
about pharmacoeconomic information in promot-
ing their products, but that is a different issue. In
terms of doing cost-beneﬁt analysis of drugs that we
approve, and other medical products we approve,
that is outside our mandate. We do not do it; we
have no plans to do it.
That said, now more than ever, the FDA needs to
make sure that in all of the steps that we impose on
the clinical trial process, on our review of applica-
tions, and on our post-market regulatory activities,
we do as much as possible to promote the public
health, at the lowest possible cost to us, and espe-
cially to society. That is why a key element that I
have been stressing, and that everyone in the agency
is focusing on right now, is what we call at the FDA
efﬁcient risk management. That is a little bit of a
mouthful for most people, but I think you all know
what I am talking about.
The FDA has long been involved in risk man-
agement activities of one kind or another, identify-
ing risks and identifying different ways of reducing
those risks. Now more than ever we are placing an
increased emphasis on efﬁciency in doing that;
ﬁnding ways to get the most beneﬁt for the public
at the least cost. And again this is a plan and
approach that is reﬂected very much in the activi-
ties of our center directors, and the professional
staff of the agency today. We are seeking to use the
best value medical science, the best risk manage-
ment science, and the best economic science to
achieve our health policy goals as efﬁciently as pos-
sible. This is important because if we can reduce
the costs and the uncertainty of developing and
distributing and using new treatments, those sav-
ings should translate into lower costs of producing
these treatments, and higher value in the health-
care system.
Earlier this year, we announced some new initi-
atives in this area. One set of initiatives focused on
ways in which we think we can help improve the
technology development process. This is a medical
innovation initiative with three main elements. One
approach includes focusing on ways to identify
causes of so-called repeat cycles in FDA reviews,
where it takes more than one agency review cycle to
get a product to market.
Another element involves applying quality sys-
tems in FDA review activities. As many of you who
are out there practicing know today, medicine,
while being a very individualized and case-speciﬁc
kind of production process (in economic parlance),
does have room to beneﬁt from identifying best
practices and taking steps to see them applied
throughout a health-care organization. We are
applying those principles to the FDA itself.
And then third, we are right now involved in a
public collaborative process for developing new reg-
ulatory guidances in important areas of product
development, like obesity, diabetes, and treatments
for cancer, and also new regulatory guidance in
some of the new areas and new approaches to prod-
uct development, where we believe the regulatory
pathway is not very clear. That includes pharmaco-
genomics, novel drug delivery systems, and salient
gene therapy. These are all areas where there is a lot
of information and a lot of research activity and
treatment development going on now, but it has not
yet fully translated into products reaching the ﬁnal
stages of development and coming to us for
approval. And we want to help that process along
as much as we can.
However, for the remainder of my remarks I
want to focus on some new activities that we are
undertaking on the postmarket side. This is because
adverse events are too common in the use of the
treatments that we regulate. As you all well know,
there are thousands of deaths, millions of potential
hospitalizations, and billions in additional costs
each year related to potentially avoidable adverse
events.  that is why a major focus of my activities at
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the FDA are on taking a fresh look and ﬁnding
some new ways to approach the FDA’s post-market
activities.
Earlier in 2003 we announced a set of these new
initiatives about what I believe is a better vision for
our post-market programs. The initiatives build on
some new opportunities that we have right now
because of legislation that was passed last year,
because of new funding, and because of new tech-
nologies being available. In terms of the new legis-
lation, as many of you know, the prescription drug
user fee act was reauthorized last year. We also had
new legislation for medical device user fees. User
fees may not sound like all that good news in them-
selves, but they provide us with some needed
resources for doing our job more effectively. In
addition, these legislative activities provided some
new authorities for FDA on the postmarket side;
authorities that we have not had before, and that we
are trying to implement right now as effectively as
possible.
To give you an idea of our direction, I want to
talk brieﬂy about some of these new policies that we
announced back in March of 2003. These are in
many ways proposed activities, or activities that are
under development, where we need and would very
much appreciate good ideas from the outside on
how we can implement them as effectively as
possible.
First, we proposed a new rule to require a uni-
versal bar coding system for prescription medica-
tions and blood products in this country. The goal
here is to develop better systems to support health
professionals and prevent avoidable errors. As many
of you know, about half of the medication errors
that occur are at the stage of dispensing and admin-
istering prescriptions. These problems relate to mak-
ing sure the right patient gets the right medication,
in the right dose, in the right form, at that right time.
There is a substantial amount of outcomes
research demonstrating that the adoption of a bar
coding system, coupled with electronic medical
records, can prevent up to half or more of those
errors. When the VA system adopted its universal
bar coding system and bar code readers, along with
electronic records, they saw their medical errors at
these stages (dispensation and administration) fall
by 80% with tremendous savings in avoidable
health-care costs, and substantial increases in the
value of the services that they provide.
We are hoping to make those kinds of savings
available nationally. The regulation that we propose
offers a universal standard for the bar codes, based
on the NDC coding system. We are asking for com-
ments on this right now as to whether it needs to be
modiﬁed, and we are deﬁnitely seeking to do this in
a way that allows additional information to be
incorporated in the bar code as time goes on, or on
a voluntary basis by product manufacturers.
While this is a proposed rule, we have heard from
a number of manufacturers that they are imple-
menting this system already. For example, Eli Lilly
expects to have bar codes on over 80% of their
products by the end of the year. And I think this is
an area where if we can set the standards, the indus-
try will move pretty quickly to adopt this system.
Not only because they think itis a good idea and rel-
atively inexpensive to adopt, but because health-
care payers, interested more than ever in demanding
value, will ask for bar codes in the health-care facil-
ities that are treating their patients because it does
lead to reduced errors. The Leapfrog Group and
others have emphasized the importance of elec-
tronic records coupled with bar coding approaches
to prevent errors. What we are trying to do is
increase the value of the health-care system by pro-
viding standards and guidance that can facilitate
private sector steps to move towards more efﬁcient
and more effective systems for delivering care.
A second proposed rule that we announced
back in March is on improving adverse event
reporting. As many of you know, we rely primarily
on our adverse event reporting system in postmar-
keting surveillance. The system relies on health
professionals working with and through product
developers and manufacturers to get information
to us, hopefully in a timely and accurate way, on
real and potential problems with the products that
they use.
But there have been a number of issues identiﬁed
with the existing system, and we are trying to
address them with the proposed rule. First, this is a
rule developed in conjunction with other regulatory
agencies around the world, through the ICH proc-
ess. So not only will it provide a basis for better
adverse event reporting in the United States, but it
will hopefully provide a basis as well for manufac-
turers involved in the adverse reporting require-
ments to produce one high quality report for any
event that occurs in the major nations around the
world where their products are used. We recognize
at the FDA that product development and medical
product use are increasingly a global market, and
anything that we can do to encourage harmoniza-
tion around the right standards for product devel-
opment and use will reduce development costs and
add value. So this is something that I think you
should expect to see more of from the FDA, in terms
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of working with other regulatory agencies to get us
all lined up in the same direction.
Second, this rule very much reﬂects our efﬁ-
cient risk management approach. Instead of ask-
ing for uniform information on each and every
adverse event that occurs, we are trying to focus
information collection and the efforts of manufac-
turers on those types of adverse events that are
most likely to tell us something new, something
that we can use in working with them and with
health professionals in improving quality of care.
So we are asking for more information on serious
adverse events, and particularly on serious adverse
events that occur in drugs that have not been on
the market very long. And conversely, we are ask-
ing for less detail than has been the case in the
past on well-understood adverse events that are
already known and that are already labeled for
products that have been on the market for some
time. It is an effort to focus our efforts, and the
efforts of the industry that we regulate, on activi-
ties that are most likely to have beneﬁt for public
health. This rule is out for comment, we would
appreciate the comments and we hope to imple-
ment it next year.
Finally, and I think more importantly, for the
long run we are developing information technology
tools that will allow us to move away from relying
only or primarily on these so-called spontaneous
adverse event reporting systems. We are moving
toward systems that take advantage of modern elec-
tronic health information technology. These are sys-
tems that will permit automatic reporting of adverse
events, in hopefully something close to real time.
The disadvantage of a spontaneous reporting sys-
tem, good as it is, and important as it is for us to
rely on today for identifying potential problems
with medications and products that we regulate, is
that it does not always work. It requires some extra
effort by health professionals who are increasingly
taxed,  increasingly  busy  with  other  activities  in
the health-care industry today. So most adverse
events go unreported, even among manufacturers
that have very good systems in place, and despite
their extensive efforts to encourage adverse event
reporting.
So we try to address that by making the adverse
event reporting system more efﬁcient, but increas-
ingly in the future we will augment that adverse
event reporting system with automatic data sys-
tems. So on our web site we have an outline of this
vision for relying much more on automatic adverse
event reporting systems. This change will occur
gradually. There is no universal national health
information infrastructure available today with
standards and high quality data elements on every-
thing that we might need to know. But there are a
number of institutions and organizations around
the country that are moving forward, and that have
information that can be very useful to us in getting
in more timely and accurate data on potential
adverse event problems that we need to know
about.
So we are doing this on a pilot basis. We are
entering to some pilot programs with the Markle
Foundation and the partnership Connecting for
Health, working with such hospitals as New York’s
Columbia Presbyterian to pilot automatic adverse
event reporting in areas where we have particular
concerns about potential risks of certain new med-
ications. We are expanding that to more hospitals
this year. We are also working with a number of
health insurance companies and health-care organ-
izations in this effort.
In our medical devices regulatory center we have
started a project called MedSun (Medical Product
Surveillance Network) that right now is collaborat-
ing with about 80 or 90 hospitals and nursing
homes, institutions that are sharing electronic data
with us on medical devices in close to real time. This
is a particularly challenging area, so those of you
who know medical devices, you all well know that
it is not only the manufacturer that matters and the
type of device, but the particular model number
because there are steady incremental changes and
improvements in medical devices. Some health-care
organizations have the ability to capture the infor-
mation that we need to monitor the use and poten-
tial adverse events problems in this way. This system
has already helped us identify more quickly several
problems with devices, and it has helped us work
with the manufacturer to quickly change devices
before many patients were exposed to risks of
adverse events. This is a program that we are going
to expand in the coming year to more than 200
institutions, and hopefully it will be expanded even
further in the future. So I think there is a lot of
potential here, in terms of better data, for the FDA
to augment its traditional reliance on spontaneous
reporting systems.
Along with this, we are improving our statistical
capabilities to make better use of these data. This is
an area where I know many of you are doing
research. I miss it myself. But there is much to be
gained from the kinds of techniques used in out-
comes research, in helping us to understand these
data on post-approval potential safety problems.
There is also much to be gained in understanding
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the longer term outcome beneﬁts, and conﬁrming
projected clinical beneﬁts among the increasing
number of products that we are approving on an
accelerated basis. So we are upgrading our statisti-
cal capabilities.
We are also doing more work in information
technology upgrades within the agency to support a
greater capacity to analyze data that we are collect-
ing now, and to analyze some of the huge reposi-
tories of data at the FDA. We have entered into
some collaborative relationships with outside
organizations. For example, the FDA recently
signed a cooperative research and development
agreement with Lincoln Technologies in Massachu-
setts, giving us access to some of the latest data min-
ing techniques that this company has been involved
in developing.
We are also making innovations in statistical
methods part of FDA’s strategic action plan, right
up there with efﬁcient risk management. Better use
of the most up-to-date statistical techniques can def-
initely help us in our job, and we are also incorpo-
rating some of these new ideas and postmarket
studies for some of the new products that we have
approved. We need to do more of this, and we need
your help, and help from the companies that many
of you all are involved with, in making more use of
these new statistical technologies.
And that brings me to the last point that I want
to make, the last major point, which is that we are
not doing any of this alone. Our activities are part
of an ongoing HHS-wide initiative. That’s made
some tremendous progress I think this spring in sup-
porting better outcomes research and better studies
of approved products.
For example, back in March the secretary made
a  major  announcement  in  which  I  participated
on information standards in health care. We
announced a set of standards for applying to gov-
ernment activities in the area of health care purchas-
ing, and (the Department of Health and Human
Services) the Department of Defense, and the
Department of Veteran’s Affairs are all together a
part of this consolidated health informatics E-Gov
initiative.
We have announced a whole set of common lan-
guages that we intend to support for the electronic
exchange of clinical health information. These
include standards for laboratory studies, for other
kinds of medical record studies and the like. We
have not covered all of the important existing and
emerging areas of medical information exchange,
but the establishment of data standards is a very
important way the government can help move for-
ward efforts to make more use of electronic infor-
mation systems. This will make clinical health
information more valuable for effective health out-
comes research.
Also, the department has now implemented, and
I think relatively successfully, the extremely com-
plex and extremely important privacy rules for
governing the use of electronic health information.
These took effect in April, and while I do not want
to pretend there have not been any bumps on the
road along the way, we have been working very
actively to address concerns about the use of pri-
vate information in ongoing research studies, both
clinical trials and outcomes research. And I want
to tell you that if you all know of any important
problems there, and serious obstacles for research
that cannot be overcome by reasonable, effective
steps to protect the conﬁdentiality of sensitive
patient information, I want to hear about them
because we really are trying to implement these
privacy rules in a way that both protects patients
and allows important research to continue.  I think
we have been reasonably successful in this
endeavor so far.
Beyond that, the FDA is collaborating more
extensively than ever with other government agen-
cies. We are doing more work with the National
Institutes of Health. Some of this has made some
press recently because it has actually helped us get
some product approvals done more quickly at the
National Cancer Institute (NCI), for a new cancer
treatment, and we are going to have more to say
about that very soon. NCI is working on expanding
a network of clinical study centers for conducting
cancer clinical trials in a standardized way, using
electronic information that they share with us on
adverse events.
We are now thinking about ways to expand post-
market monitoring and postmarket studies, and I
think that area has a lot of promise. We are working
with many of the other NIH Institutes as well.
Finally, we will be working more with the Cent-
ers for Disease Control as well in their steps to
improve the public health information infrastruc-
ture, which we need very badly today to improve
our surveillance capabilities to monitor for emerg-
ing diseases and potential terrorist threats. So on all
of these areas we are working very well with gov-
ernment agencies.
I want to open the door for more collaboration
with the private sector too. You all have many new
ideas about more effective ways to get the informa-
tion that we need on outcomes and on the value of
new medical innovations and their impact on
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health, and I hope that we can do more of that in
the months and years ahead as well.
I want to close by emphasizing that we need to
do more, all of us, to focus on improving value in
health care. I know that has always been one of the
main areas of emphasis of this organization, and I
know you are renewing your focus in that area
going forward. But the future of medical care is very
uncertain today. I can stand up here and honestly
paint these different pictures of a future with limited
innovation, maybe good cost control, but not much
added value going forward, and a future that I think
is much brighter, and that I think we can work
together to meet, with a lot of innovation and a lot
of higher value in health care delivery at the same
time.
But this is not going to be easy; it is not going to
be easy for us at FDA, not for health policymakers
here in the Washington area in general, nor for the
industries that we regulate. We need guidance from
experts like you on how we can accomplish this job
more effectively. We need to address issues relating
to the affordability of health care, while still encour-
aging the kind of innovation and steady improve-
ments in value that have led so many Americans to
expect improvements in health care going forward.
This is a critical time for health policy, a critical
time for us to work together to meet these chal-
lenges, and at the FDA we are doing more than ever
to address the challenges. I very much hope that all
of you can be our partners in this effort as we try
again, and try harder and better, to bring new med-
ical technologies to the greatest number of people
that can safely beneﬁt from them. That is our mis-
sion at FDA, to both protect and advance the public
health. It is our goal as participants in the health-
care enterprise. I know it is a goal that you all share
in your work in pharmacoeconomics and outcomes
research. And I know it is in the best interest of the
American people as well.
